AI assistant
Sending…
NovoCure Ltd — Director's Dealing 2015
Oct 1, 2015
31949_dirs_2015-10-01_987ee007-7b83-4652-b3b6-31fe0c697a13.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Novocure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2015-10-01
Reporting Person: PHILLIPS CHARLES G III (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Options to Buy Ordinary Shares | $6.72 | 2022-09-29 | Ordinary Shares (162607) | Direct | |
| Series F Convertible Preferred Shares | $ | Ordinary Shares (44856) | Indirect | ||
| Series G Convertible Preferred Shares | $ | Ordinary Shares (5333) | Indirect | ||
| Series H Convertible Preferred Shares | $ | Ordinary Shares (3701) | Indirect | ||
| Series I Convertible Preferred Shares | $ | Ordinary Shares (10672) | Indirect | ||
| Series J Convertible Preferred Shares | $ | Ordinary Shares (3843) | Indirect |
Footnotes
F1: Options to buy 121,955 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 40,652 ordinary shares will vest and become exercisable on September 29, 2016, subject to Mr. Phillips's continued service through such date.
F2: Pursuant to the issuer's memorandum & articles of association, all outstanding preferred shares of each series will automatically convert into ordinary shares upon consummation of the issuer's initial public offering.
F3: N/A
More from NovoCure Ltd
Proxy Solicitation & Information Statement
2026
May 21
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 24
Regulatory Filings
2026
Apr 9
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3